| abstract |
An IL-6 antagonist for use in a method of treating hepcidin-mediated chronic inflammatory anemia in a patient, the method comprising administering a therapeutically effective amount of said IL-6 antagonist to said patient, wherein determined that the patient has at least one copy of the TMPRSS6 rs855791 major allele, optionally wherein this has previously been determined or wherein said method comprises a prior step of determining whether said patient has at least one copy of the TMPRSS6 rs855791 major allele TMPRSS6; wherein the IL-6 antagonist is: (a) an anti-IL-6 antibody, or antigen-binding fragment or derivative thereof; or (b) an anti-IL-6R antibody, or antigen-binding fragment or derivative thereof, optionally tocilizumab or vobarilizumab. |